Frontier Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Frontier Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,190	Closed	-$388K	–	401
2016 Q3	$388K	Sell	4,190 -26	-0.6%	-$2.45K	0.06%	244
2016 Q2	$328K	Sell	4,216 -200	-5%	-$17K	0.05%	266
2016 Q1	$364K	Sell	4,416 -450	-9%	-$36.6K	0.03%	237
2015 Q4	$510K	Hold	4,866	–	–	0.08%	197
2015 Q3	$512K	Buy	4,866 +50	+1%	+$6.68K	0.08%	207
2015 Q2	$659K	Buy	+4,816	New	+$597K	0.1%	170

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Frontier Wealth Management's BMRN Position: Q4 2016 in Review

Frontier Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 4,190 shares — an estimated $388K sold.

Frontier Wealth Management first reported a position in BMRN in Q2 2015 and held it in 6 quarters. The position peaked at $659K in Q2 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

Frontier Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Frontier Wealth Management sold 4,190 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $388K.
Frontier Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Frontier Wealth Management's BioMarin Pharmaceuticals position peaked at $659K in Q2 2015.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Frontier Wealth Management's 13F filing for Q4 2016, filed 10 Feb 2017.